{"ATC Code":"A - Alimentary tract and metabolism","Abbreviation":[],"Aliases":["n-butylscopolammonium","N-butylscopolammonium ion","N-butylscopolammonium cation","butylscopolammonium","butilescopolamina","(7(S)-(1α,2β,4β,5α,7β))-9-Butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azonitricyclo(3.3.1.0(2,4))nonane","3-Oxa-9-azonitricyclo(3.3.1.0(2,4))nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, (7(S)-(1α,2β,4β,5α,7β))-","(2R,4S,5S,7s)-9-butyl-7-(((2S)-3-hydroxy-2-phenylpropanoyl)oxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane","(2R,4S,5S,7s)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane","Scopolamine N-N-Butyl","RefChem:54585","3-Oxa-9-Azoniatricyclo(3.3.1.0 Sup(2,4))Nonane,9-Butyl-7-((2S)-3-Hydroxy-1-Oxo-2-Phenylpropoxy)-9-Methyl-, (1α,2β,4β,5α,7β)-","n-butylscopolamine","Sr-01000759230","butylscopolamine-bromide","Bromide, Butylscopolammonium","HMS2090N11","DB09300","Ncgc00386439-01","Ab00639613-11","Sr-01000759230-4","3-Oxa-9-azoniatricyclo(3.3.1.0 sup(2,4))nonane,9-butyl-7-((2s)-3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, (1α,2β,4β,5α,7β)-"],"Biological Half-Life":"The half life of elimination is 1-5 hours.","CAS":"7182-53-8","ChEBI":"CHEBI:145701","ChEMBL":"CHEMBL1618102","ChemicalClasses":["tropane"],"Chirality":"absolute","Classes":["Anticholinergic"],"Drug Indication":"Used to treat abdmoninal cramping and pain.","Drug Warnings":"Changes in cardiopulmonary function of elderly patients during upper gastrointestinal endoscopy to examine the effects of antispasmodics ... was conducted on 174 subjects older than 60 years (101 male and 73 female, mean age 71.0). Subjects were divided into 3 groups based on the antispasmodic used for pre-medication: 76 received recombinant glucagon (Group G); 63 scopolamine butylbromide (group B); and 35 had no antispasmodic (group N). After informed consent a pulse oximeter was used to measure heart rate and oxygen saturation at five points during the endoscopic procedure. Maximum heart rate increase and oxygen saturation decrease occurred in all groups when the endoscope passed through the esophago-cardiac junction. Heart rate was significantly higher in group B than G or N after administration of antispasmodic drugs. Scopolamine butylbromide should be administered with caution in upper gastrointestinal endoscopy of elderly patients because it may increase cardiac load. /Scopolamine butylbromide/","DurationOfAction":"","EliminationHalfLife":"5 hours","Esters":[],"Formating":[],"HeavyAtomCount":26,"Human Drugs":"Pharmaceuticals","IUPACName":"[(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate","InChI":"InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1","InChIKey":"YBCNXCRZPWQOBR-MWGADRMYSA-N","Interactions":"Concomitant administration of dopamine receptor antagonists such as metoclopramide can reduce the effect of both drugs on the GI tract. Hyoscine butylbromide can increase the tachycardic effect of beta-adrenoceptor agonists (beta-blockers). /Hyoscine butylbromide/","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e30\u003c/sub\u003eNO\u003csub\u003e4\u003c/sub\u003e+","MolecularWeight":"360.5 g/mol","Opticalactivity":"UNSPECIFIED","PD":"PD132842","Pharmacodynamics":"Scopolamine butylbromide is a muscarinic antagonist which acts to prevent acetylcholine-stimulated contraction of smooth muscle in the gastrointestinal tract.","PubChemId":160883,"RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Hyoscine butylbromide","Name":"Butylscopolamine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q27255822","Name":"Butylscopolamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB09300","Name":"Butylscopolamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/160883","Name":"Butylscopolamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1618102","Name":"Butylscopolamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145701","Name":"Butylscopolamine","Sub":false}]},{"Name":"Probes \u0026 Drugs","Urls":[{"Link":"https://www.probes-drugs.org/compound/PD132842","Name":"Butylscopolamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=7182-53-8","Name":"Butylscopolamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/2Z3E1OF81V","Name":"Butylscopolamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4048145","Name":"Butylscopolamine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 160883, Butylscopolamine. Accessed September 14, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/160883\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/160883\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Butylscopolamine. UNII: 2Z3E1OF81V. Global Substance Registration System. Accessed September 14, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2Z3E1OF81V\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/2Z3E1OF81V\u003c/a\u003e","Hyoscine Butylbromide (AFT Pharmaceuticals Pty Ltd). Accessed September 14, 2025. \u003ca href=https://www.tga.gov.au/resources/prescription-medicines-registrations/hyoscine-butylbromide-aft-pharmaceuticals-pty-ltd\u003ehttps://www.tga.gov.au/resources/prescription-medicines-registrations/hyoscine-butylbromide-aft-pharmaceuticals-pty-ltd\u003c/a\u003e"],"SMILES":"CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C","SaltData":[],"Salts":[],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S2 substance"},{"gov":"Canada","ref":[],"schedule":"OTC (Pharmacist only) substance"},{"gov":"United Kingdom","ref":[],"schedule":"GSL substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 56.655 153.276\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h57v154H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m39.896 152.223-9.775-11.693M30.121 140.53l5.239-14.311M35.36 126.219l-9.775-11.692M25.585 114.527l2.847-15.977\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m46.459 91.407-.145-.685-12.53 1.382.33 1.559.33 1.559z\" class=\"bond\"/\u003e\u003cpath d=\"m46.386 91.064-3.454-14.833M42.932 76.231l-13.716-6.604M29.216 69.627 15.5 76.231M15.5 76.231l-3.353 14.833\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m12.221 90.722-.148.684 13.361 4.322.371-1.72.37-1.719z\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M21.604 103.292a.36.36 0 0 1-.282-.123l-.455-.571.541-.445.462.581q.016-.016.028-.016c.074 0 .039.409-.085.507a.33.33 0 0 1-.209.067m-1.937-2.204-7.794-9.806a.38.38 0 0 1 .056-.492.34.34 0 0 1 .209-.067c.109 0 .219.043.283.123l7.787 9.797z\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M21.596 103.302c-.175 0-.35-.176-.35-.351s.175-.35.35-.35h5.093l-.117.701zm6.932 0 .117-.701h8.191a.14.14 0 0 1 .099-.047c.136 0 .251.256.251.397 0 .175-.175.351-.35.351z\" class=\"bond\"/\u003e\u003cpath d=\"m46.386 91.064-9.55 11.887\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"m37.139 103.126-.606-.35-6.777 9.141 1.427.824 1.428.824zM26.917 112.928l.462-2.76 1.294 1.746-1.427.824zm-1.794-.969-3.83-8.833.606-.35 3.884 5.24z\" class=\"bond\"/\u003e\u003cpath d=\"M29.216 69.627V58.308M25.932 52.491l-9.915-5.724\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M17.237 47.471 6.707 53.55M16.017 45.359 5.488 51.438\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m6.707 53.55 5.265-3.04M5.488 51.438l5.264-3.04\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"M16.017 46.767v-15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M16.017 31.177v.7M14.132 29.838v1.2M12.247 28.499V30.2M10.361 27.161v2.2M8.476 25.822v2.701M6.59 24.484v3.2M4.705 23.145v3.7M2.819 21.806v4.201\"/\u003e\u003c/g\u003e\u003cpath d=\"M2.819 23.907V12.588M16.017 31.527l13.199-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m29.211 8.658.005 15.249M31.65 10.066l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m29.211 8.658 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M55.612 8.667 42.409 1.038M53.174 10.074l-10.765-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m55.612 8.667.005 15.248\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m42.419 31.535 13.198-7.62M42.419 28.719l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m29.216 23.907 13.203 7.628M26.083 97.164l-12.632 10.181\" class=\"bond\"/\u003e\u003cg fill=\"#3050f8\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M31.055 97.172h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.054h.03l-.018-.327-.024-.476q-.006-.262-.006-.483v-2.768h.578zM32.731 92.128h.818v.292h-.818v.847h-.297v-.847h-.818v-.292h.818v-.851h.297z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M31.475 116.147q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.245-.571-.245-1.333 0-.75.245-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453M31.475 54.384q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.245-.571-.245-1.333 0-.75.245-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453M5.078 54.384q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg fill=\"#ff0d0d\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M5.078 8.664q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887Q.56 9.414.56 8.652q0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M9.385 11.116h-.62V8.83H6.253v2.286H5.64V6.217h.613v2.072h2.512V6.217h.62z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m28.805 118.379 1.668 1.994\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m28.432 98.55-1.424 7.988M28.432 98.55l-1.424 7.988\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m25.585 114.527 1.423-7.989M29.216 58.308v5.66M25.932 52.491l-4.958-2.862M2.819 12.588v5.659M2.819 12.588v5.659\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m26.083 97.164-6.316 5.091\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":null,"Therapeutic Uses":"Hyoscine butylbromide (scopolamine butylbromide) is an antispasmodic drug indicated for the treatment of abdominal pain associated with cramps induced by gastrointestinal (GI) spasms. It was first registered in Germany in 1951 and marketed in 1952, and has since become available worldwide both as a prescription drug and as an over-the-counter medicine in many countries. /Hyoscine butylbromide/","Title":"Butylscopolamine","UNII":"2Z3E1OF81V","Wikidata":"Q27255822","Wikipedia":"Hyoscine butylbromide","XLogP":2.6}